Efficacy and Safety of 5 mg Olanzapine Added to Standard Antiemetics for Breast Cancer Chemotherapy: Insights from a Phase 3 Double-Blind Trial

Highlights

• Post-chemotherapy administration of 5 mg olanzapine significantly increases the complete response rate for chemotherapy-induced nausea and vomiting (CINV) compared to placebo when added to standard triplet antiemetics.
• Olanzapine at this lower dose demonstrates a favorable safety profile, with low rates of sedation and cognitive impairment.
• Severe anorexia and constipation were less frequent in the olanzapine group than in the placebo group.

Clinical Background and Disease Burden

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects for patients undergoing highly emetogenic chemotherapy, particularly with anthracycline plus cyclophosphamide regimens commonly used in early-stage breast cancer. Despite advances and guideline-driven use of triplet antiemetic regimens (5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone), a significant proportion of patients still experience breakthrough symptoms, leading to poor quality of life, decreased treatment adherence, and increased healthcare utilization. Previous studies demonstrated that adding 10 mg olanzapine to standard antiemetic therapy provides further benefit but increases the risk of sedation and cognitive impairment, which can be problematic for outpatient populations.

Research Methodology

This multicenter, phase 3, double-blind, randomized, placebo-controlled trial was conducted at 15 hospitals and cancer centers across Japan. Female adults (≥20 years) with stage I-III breast cancer, ECOG PS 0-1, and scheduled for intravenous anthracycline plus cyclophosphamide chemotherapy, who were chemotherapy-naive or had not received moderately/highly emetogenic regimens, were eligible. Participants (n=500) were randomized (1:1) to receive oral olanzapine 5 mg or placebo. Stratification was by age (≥55 vs <55) and institution.

All patients received standard triplet antiemetics: intravenous dexamethasone, intravenous palonosetron, and an NK1 receptor antagonist (aprepitant or fosaprepitant). Study drug was administered at home within five hours post-chemotherapy on day 1 and after the evening meal for the next three days. The primary endpoint was the complete response rate (no vomiting, no rescue medication) during the overall phase (0-120 hours post-chemotherapy), assessed via patient diaries. Modified intention-to-treat analyses included all patients who received at least one study dose and had efficacy data. Safety was assessed in all treated patients.

Key Findings

Of 500 randomized patients, 480 (246 olanzapine, 234 placebo) were evaluable for efficacy. The median age was 52 years. The complete response rate for the overall phase was significantly higher in the olanzapine group (58.1%) than in the placebo group (35.5%), yielding an absolute difference of 22.7% (95% CI 14.0–31.4%; p<0.0001). These results confirm a meaningful clinical benefit for the addition of 5 mg olanzapine.

Severe or very severe patient-reported anorexia occurred less in the olanzapine group (13%) compared to placebo (38%). Constipation was also less frequent (12% vs 16%). Severe or very severe concentration impairment was reported in 10% (olanzapine) and 14% (placebo). Grade 3-4 somnolence was rare (2% olanzapine, 0% placebo), as was grade 3-4 concentration impairment (1% olanzapine, 0% placebo). There were no deaths related to study drug.

Mechanistic Insights

Olanzapine is an atypical antipsychotic with potent antagonism of multiple neurotransmitter receptors implicated in emesis, including dopamine D2, serotonin 5-HT2, and muscarinic receptors. Its efficacy in CINV likely arises from broad-spectrum antiemetic activity. The lower 5 mg dose, administered post-chemotherapy and in the evening, appears to retain efficacy while minimizing sedative effects—possibly by aligning peak plasma levels with the period of greatest emetogenic risk and sleep, thus optimizing tolerability.

Expert Commentary

Current international guidelines (ASCO, NCCN, MASCC/ESMO) endorse olanzapine for highly emetogenic regimens, but concerns persist regarding sedation, especially with 10 mg dosing. This study’s outpatient, evening-administration protocol addresses these concerns and supports guideline adaptation for lower-dose, post-chemotherapy olanzapine in breast cancer patients on anthracycline-cyclophosphamide regimens.

Controversies or Limitations

Limitations include the restriction to Japanese female patients; generalizability to other ethnicities, male patients, or other cancer types requires further study. The study did not collect data on gender diversity or ethnicity/race. The follow-up period was short, limited to the acute/subacute CINV window, and the effects on subsequent cycles or long-term cognitive outcomes are unknown. Additionally, the study did not directly compare 5 mg and 10 mg olanzapine, so the relative efficacy and safety between doses remain to be established.

Conclusion

This pivotal trial demonstrates that 5 mg olanzapine, administered at home after anthracycline plus cyclophosphamide chemotherapy and combined with standard triplet antiemetics, significantly improves CINV control with an acceptable safety profile for outpatient breast cancer patients. The findings support the incorporation of lower-dose, post-chemotherapy olanzapine into antiemetic protocols, potentially enhancing patient quality of life and treatment adherence while minimizing sedative side effects. Future research should address long-term use, other populations, and direct comparison with higher doses.

References

Saito M, Iihara H, Shimokawa M, Udagawa R, Tsuneizumi M, Futamura M, Ishikawa Y, Ogata H, Bando H, Shima H, Hosoya K, Mukohara T, Tanaka K, Ikuta T, Kawate T, Ishida K, Nakai K, Uomori T, Kutomi G, Ozeki R, Yanagisawa N. Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2025 Jul;26(7):960-970. doi: 10.1016/S1470-2045(25)00233-5.

Additional guideline references:
– National Comprehensive Cancer Network (NCCN) Guidelines: Antiemesis. Version 1.2024.
– ASCO Antiemetic Guidelines Update. J Clin Oncol. 2023;41(2):178-200.